Cephalon

November 9, 2007 -- "This agreement in principal - the result of an unprecedented investigative partnership between Connecticut and the U.S. Attorney's Office in Philadelphia - will return millions of dollars to the Medicaid program. If it becomes final, the Cephalon settlement by no means ends Connecticut's intensive ongoing investigation into the company's off-label marketing.    » read more »

September 13, 2007 -- "Today's report by Cephalon tragically confirms concerns raised by our aggressive investigation into Cephalon's off-label marketing of its drugs. News of confirmed deaths and other adverse reactions adds urgency and immediacy to our active and ongoing investigation. Our serious and significant concerns about this drug, already substantiated by evidence, are likely to support efforts for remedial action.    » read more »